H.C. Wainwright raised the firm’s price target on Personalis (PSNL) to $13 from $10 and keeps a Buy rating on the shares after the company received Medicare reimbursement for post-treatment monitoring for cancer recurrence in patients with stage II and III breast cancer. Encouragingly, the reimbursement is effective retroactively starting October 7, at a rate of $3,878 for the initial test and $1,158 for follow-up tests, the analyst tells investors in a research note.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PSNL:
- Midday Fly By: Insurers slip as Senate spending bill lacks ACA extension
- Personalis Secures Medicare Coverage for NeXT Personal MRD Test, Positioning for Growth in Underpenetrated $20 Billion Market
- Personalis Gains Medicare Coverage for Cancer Test
- Personalis announces Medicare coverage of NeXT Personal test
- Personalis price target raised to $10 from $8.50 at H.C. Wainwright